// App-Quantinova.ai

5053 : IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Charles J. Ryan

Principal Investigators

  • E David Crawford

  • Shawn C. Black

  • Tracy McGowan

  • Philip W. Kantoff

  • Neal D. Shore

  • Willie Underwood

  • Anil Londhe

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

  • Janssen Pharmaceuticals, Horsham, PADana-Farber Cancer Institute and Harvard Medical School, Boston, MAJanssen Research and Development, Horsham, PA

  • University of Colorado Hospital, Aurora, CO

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Carolina Urologic Research Center, Myrtle Beach, SC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved